During the last session, Travere Therapeutics Inc (NASDAQ:TVTX)’s traded shares were 1.38 million, with the beta value of the company hitting 0.80. At the end of the trading day, the stock’s price was $19.41, reflecting an intraday loss of -1.47% or -$0.29. The 52-week high for the TVTX share is $25.29, that puts it down -30.29 from that peak though still a striking 73.62% gain since the share price plummeted to a 52-week low of $5.12. The company’s market capitalization is $1.72B, and the average trade volume was 1.53 million shares over the past three months.
Travere Therapeutics Inc (TVTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.13. TVTX has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.36.
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Travere Therapeutics Inc (TVTX) registered a -1.47% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.47% in intraday trading to $19.41, hitting a weekly high. The stock’s 5-day price performance is -7.70%, and it has moved by -4.01% in 30 days. Based on these gigs, the overall price performance for the year is 146.63%.
The consensus price target of analysts on Wall Street is $23, which implies an increase of 15.61% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $33 respectively. As a result, TVTX is trading at a discount of -70.02% off the target high and 7.26% off the low.
Travere Therapeutics Inc (TVTX) estimates and forecasts
In the rating firms’ projections, revenue will increase 68.00% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 77.53M as predicted by 12 analyst(s). Meanwhile, a consensus of 12 analyst(s) estimates revenue growth to 89.56M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 41.37M and 54.12M respectively. In this case, analysts expect current quarter sales to grow by 87.38% and then jump by 65.50% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -3.34%. While earnings are projected to return 70.49% in 2025.
TVTX Dividends
Travere Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 7.5 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 9.6774% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $61.65 million.
Also, the Mutual Funds coming in first place with the largest holdings of Travere Therapeutics Inc (TVTX) shares are Delaware Group Equity Fds V-Small Cap Core Fund and Vanguard Total Stock Market Index Fund . Data provided on Nov 30, 2024 indicates that Delaware Group Equity Fds V-Small Cap Core Fund owns about 3.45 shares. This amounts to just over 3.89 percent of the company’s overall shares, with a $67.0 million market value. The same data shows that the other fund manager holds slightly less at 2.51, or about 2.82% of the stock, which is worth about $48.63 million.
